Founded by Stéphane Ragusa, who has a qualification from the Ecole Polytechnique and from ENSAE (École nationale de la statistique et de l’administration économique (in English, the National School of Statistics and Economic Administration), as well as a PhD in Biology, Predilife develops innovative solutions in the field of predictive medicine combining proven medical techniques (genetic testing, medical imaging, etc.) and mathematical models using a large amount of statistical data, which could enable individuals to define their risk profile regarding the occurrence of a wide range of serious diseases.

PrediLife History
  1. Creation of Predilife by Stéphane Ragusa.
  2. Contract with INSERM to access their data cohorts.
  3. Contract with BCSC to access their database on 1,000,000 American women.
  4. Collaboration contract with the Gustave-Roussy institute.
  5. Import of the model developed by Predilife on 300,000 French women - MammoRisk® score.
  6. Symposium about the MammoRisk® test regarding the possibility of predicting breast cancer, organised in the context of the annual Société Française d’Imagerie de la Femme (SIFEM - French Women’s Imaging Society) congress.
  7. Implementation of the Riviera clinical study.
  8. FDA approval for DenSeeMammo with General Electric devices.
  9. 1st MammoRisk® & DenSeeMammo sale.
  10. PrediLife entering the stock market.
  11. Collaboration contract with l’Institut Curie.

Our Vision

Predilife develops predictive tests for medicine of the future: Predictive, Preventive, Personalised and Participatory (P4). Predictive medicine involves predicting the future of an individual in order to act in a timely manner thanks to personalised prevention, either by lowering the risks (known as primary prevention), or by identifying the illness sooner (secondary prevention). Major diseases, cancers and cardiac arrest in particular, could be prevented in a more effective manner, thereby decreasing their death rate by at least 30%. Still, each person’s health trajectory is needed to act whilst there’s still time.

medecine 4p